-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Allogeneic Donor-Derived T-Cells Transduced With Bivalent Lentiviral Vector (CD19/CD22-BBz) Chimeric Antigen Receptor (CAR) in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Allogeneic Donor-Derived T-Cells Transduced With Bivalent Lentiviral Vector (CD19/CD22-BBz) Chimeric Antigen Receptor (CAR) in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using...
-
Company Insights
Innovation and Patenting activity of Vector Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vector Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval Analysis for Flaviviridae Infections
Overview How likely is it that the drugs in Flaviviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Flaviviridae Infections Overview Fiavivirideae infections are caused by a family of enveloped...
-
Company Insights
Innovation and Patenting activity of Vector Group Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vector Group Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Track & Monitor
Innovation in automotive: Torque vectoring
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the automotive industry’s Torque vectoring segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-710 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-710 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-710 in Cystic Fibrosis Drug Details: 4D-710 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HGTV-43 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HGTV-43 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HGTV-43 in Human Immunodeficiency Virus (HIV) Infections (AIDS)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – THV-01 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - THV-01 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. THV-01 in Human Immunodeficiency Virus (HIV) Infections (AIDS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VXAG-1.1NN in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VXAG-1.1NN in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VXAG-1.1NN in Norovirus Infections Drug Details: VXAG-1.1NN is under development for the prevention...